Fourth-quarter data for the little guys

Evaluate Vantage has already delved into the key upcoming fourth-quarter data for big pharma and large biotech groups. Now it is the turn of companies with a market cap under $1bn.

Relmada will reveal the first late-stage results with its depression project REL-1017, although concerns over abuse potential could hinder its commercial prospects. Elsewhere, Albireo and Mirum are jostling for space in the rare paediatric biliary disorder market.